Skip to main content
. 2021 Nov 27;21:388. doi: 10.1186/s12890-021-01754-6

Table 2.

Description of the study patients and the relationship between the clinical variables with persistence to inhalers

Variables Persistence
Yes (46, 40.4%) No (68, 59.6%) p value
Visits to GP 0.040
  ≤ 6 months 19 (73.1) 19 (47.5)
  > 6 months 7 (26.9) 21 (52.5)
Visits to the Emergency Service in the last 12 months 0.361
 No 36 (78.3) 48 (70.6)
 Yes 10 (21.7) 20 (29.4)
COPD 0.535
 Mild + moderate 35 (85.4) 59 (89.4)
 Severe + very severe 6 (14.6) 7 (10.6)
Knowledge about COPD severity and chronicity 0.011
 No 18 (39.1) 43 (63.2)
 Yes 28 (60.9) 25 (36.8)
To receive explanation about treatment 0.223
 No 27 (58.7) 32 (47.1)
 Yes 19 (41.3) 36 (52.9)
Number of inhalers 0.110
 1 32 (69.6) 56 (82.4)
 2/3 14 (30.4) 12 (17.6)
Health related quality of life (mean, sd)
 Symptoms 35.7 (27.2) 46.7 (20.4) 0.522
 Activity 38.9 (27.2) 46.7 (20.4) 0.026
 Impact 43.9 (27.2) 46.7 (20.4) 0.227
 Total 36.0 (17.1) 41.4 (13.4) 0.023
Inhaler device types 0.021
 Single dose DPI 21 (42.9) 28 (57.1)
 Multidose DPI 10 (25.6) 29 (74.4)
 SMI 8 (57.1) 6 (42.9)
 MDI 7 (58.3) 5 (41.7)

DPI dry powder inhalers, SMI soft mist inhaler, MDI metered dose inhalers, GP general practitioner, COPD chronic obstructive pulmonary disease